Phase 3 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis
Based on preclinical and clinical evidence of an antifibrotic mechanism, two Phase 3 randomized trials of treprostinil as inhaled prescription therapy were conducted for treatment of idiopathic pulmonary fibrosis (IPF). The publication reports the results of the double-blind TETON 1 trial, in which patients with IPF were randomly assigned the inhalation of the experimental drug…